دورية أكاديمية
COVID-19 and liver injury: An ongoing challenge.
| العنوان: | COVID-19 and liver injury: An ongoing challenge. |
|---|---|
| المؤلفون: | Papagiouvanni I; Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Thessaloniki, Greece. ioanna.d.pap@gmail.com., Kotoulas SC; Intensive Care Unit, Hippokration General Hospital, Thessaloniki 54642, Greece., Pataka A; Department of Respiratory Medicine, G Papanikolaou Hospital, Resp Failure Unit, Aristotle University of Thessaloniki, Thessaloniki 57001, Greece., Spyratos DG; Pulmonary Department, Aristotle University of Thessaloniki, Thessaloniki 57001, Greece., Porpodis K; Pulmonary Department, Aristotle University of Thessaloniki, Thessaloniki 57001, Greece., Boutou AK; Pulmonary Department, G Papanikolaou Hospital, Resp Failure Unit, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece., Papagiouvannis G; Department of Pharmacy, School of Health Sciences, Frederick University, Nicosia 1036, Cyprus., Grigoriou I; Respiratory Failure Clinic, Papanikolaou General Hospital, Thessloniki 57001, Greece., Vettas C; Fourth Department of Internal Medicine, Hippokration General Hospital, Thessaloniki 54642, Greece., Goulis I; Fourth Department of Internal Medicine, Hippokration General Hospital, Thessaloniki 54642, Greece. |
| المصدر: | World journal of gastroenterology [World J Gastroenterol] 2023 Jan 14; Vol. 29 (2), pp. 257-271. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing : WJG Press, c1998- |
| مواضيع طبية MeSH: | COVID-19* , Carcinoma, Hepatocellular* , Liver Neoplasms*, Humans ; SARS-CoV-2 |
| مستخلص: | The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019, in Wuhan, China. The virus was rapidly spread worldwide, causing coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is presented, usually, with typical respiratory symptoms ( i.e. , dyspnea, cough) and fever, extrapulmonary manifestations are also encountered. Liver injury is a common feature in patients with COVID-19 and ranges from mild and temporary elevation of liver enzymes to severe liver injury and, even, acute liver failure. The pathogenesis of liver damage is not clearly defined; multiple mechanisms contribute to liver disorder, including direct cytopathic viral effect, cytokine storm and immune-mediated hepatitis, hypoxic injury, and drug-induced liver toxicity. Patients with underlying chronic liver disease ( i.e. , cirrhosis, non-alcoholic fatty liver disease, alcohol-related liver disease, hepatocellular carcinoma, etc .) may have greater risk to develop both severe COVID-19 and further liver deterioration, and, as a consequence, certain issues should be considered during disease management. The aim of this review is to present the prevalence, clinical manifestation and pathophysiological mechanisms of liver injury in patients with SARS-CoV-2 infection. Moreover, we overview the association between chronic liver disease and SARS-CoV-2 infection and we briefly discuss the management of liver injury during COVID-19. Competing Interests: Conflict-of-interest statement: Authors declare no conflict of interests for this article. (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | J Hepatol. 2021 Apr;74(4):944-951. (PMID: 33563499) J Viral Hepat. 2020 Dec;27(12):1504-1507. (PMID: 32668494) Medicina (Kaunas). 2022 Jan 18;58(2):. (PMID: 35208467) Ann Oncol. 2020 Jul;31(7):894-901. (PMID: 32224151) J Gastrointestin Liver Dis. 2020 Jun 03;29(2):219-226. (PMID: 32530989) N Engl J Med. 2020 Aug 6;383(6):590-592. (PMID: 32402155) World J Clin Cases. 2021 May 26;9(15):3487-3497. (PMID: 34046449) Vaccine. 2006 Mar 20;24(13):2417-22. (PMID: 16406176) Int Immunopharmacol. 2021 Jul;96:107763. (PMID: 34162141) World J Clin Cases. 2022 Mar 6;10(7):2063-2071. (PMID: 35321162) J Hepatol. 2020 Aug;73(2):451-453. (PMID: 32278005) J Hepatol. 2021 Jun;74(6):1295-1302. (PMID: 33347952) J Hepatol. 2020 Oct;73(4):807-816. (PMID: 32437830) Am J Clin Pathol. 2021 May 18;155(6):802-814. (PMID: 33914058) J Clin Med. 2020 Mar 30;9(4):. (PMID: 32235486) Hepatology. 2021 Oct;74(4):1750-1765. (PMID: 33961298) Clin Gastroenterol Hepatol. 2021 Mar;19(3):597-603. (PMID: 32553907) Liver Int. 2021 Sep;41(9):1988-1998. (PMID: 34152690) Immunopharmacol Immunotoxicol. 2021 Feb;43(1):1-7. (PMID: 32883116) JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570) Eur J Gastroenterol Hepatol. 2021 Jul 1;33(7):990-995. (PMID: 32639420) Liver Int. 2021 Oct;41(10):2527-2528. (PMID: 34478591) J Hepatol. 2020 Nov;73(5):1063-1071. (PMID: 32526252) J Hepatol. 2021 Mar;74(3):567-577. (PMID: 33035628) Liver Int. 2020 Sep;40(9):2095-2103. (PMID: 32239796) N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013) World J Clin Cases. 2022 Feb 6;10(4):1140-1163. (PMID: 35211548) Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):13072-13088. (PMID: 33378061) World J Hepatol. 2021 Dec 27;13(12):2013-2023. (PMID: 35070005) Clin Gastroenterol Hepatol. 2021 Jul;19(7):1355-1365.e4. (PMID: 33010411) J Hepatol. 2021 Jun;74(6):1335-1343. (PMID: 33508378) Aliment Pharmacol Ther. 2020 Sep;52(6):1051-1059. (PMID: 32697870) J Hepatol. 2022 Mar;76(3):740-742. (PMID: 34813919) Dig Dis Sci. 2022 Aug;67(8):4204-4214. (PMID: 34487314) J Hepatol. 2020 Sep;73(3):719-721. (PMID: 32348790) Hepatol Int. 2020 Sep;14(5):612-620. (PMID: 32725453) World J Hepatol. 2021 May 27;13(5):522-532. (PMID: 34131467) Hepatology. 2020 Jul;72(1):287-304. (PMID: 32298473) Diabetes Metab Syndr. 2021 May-Jun;15(3):813-822. (PMID: 33862417) F1000Res. 2021 May 18;10:400. (PMID: 34900226) J Dig Dis. 2020 Sep;21(9):512-518. (PMID: 32713118) J Hepatol. 2019 Jun;70(6):1222-1261. (PMID: 30926241) Vaccines (Basel). 2022 Jan 26;10(2):. (PMID: 35214651) World J Hepatol. 2020 Dec 27;12(12):1299-1313. (PMID: 33442456) J Hepatol. 2020 Dec;73(6):1566-1568. (PMID: 32890595) Clin Gastroenterol Hepatol. 2021 Aug;19(8):1726-1729.e3. (PMID: 33516952) JAMA Intern Med. 2021 Oct 1;181(10):1306-1314. (PMID: 34254978) Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19. (PMID: 32950749) J Gastroenterol. 2021 Mar;56(3):218-230. (PMID: 33527211) Liver Int. 2022 Mar;42(3):607-614. (PMID: 34846800) Front Med (Lausanne). 2020 Oct 20;7:584342. (PMID: 33195339) Gastroenterology. 2020 Aug;159(2):768-771.e3. (PMID: 32376408) Gut. 2020 Aug;69(8):1545-1547. (PMID: 32414813) Liver Int. 2020 Oct;40(10):2515-2521. (PMID: 32585065) Liver Int. 2020 Sep;40(9):2110-2116. (PMID: 32654359) Gut. 2021 Mar;70(3):531-536. (PMID: 32660964) J Gastroenterol Hepatol. 2021 Jan;36(1):204-207. (PMID: 32436622) J Med Virol. 2021 Jan;93(1):250-256. (PMID: 32592501) Hepatology. 2020 Oct;72(4):1169-1176. (PMID: 32725890) World J Hepatol. 2021 Sep 27;13(9):1143-1153. (PMID: 34630881) Gut. 2021 Mar;70(3):628-629. (PMID: 32571973) Gut. 2022 Nov;71(11):2350-2362. (PMID: 35701093) Nat Metab. 2022 Mar;4(3):310-319. (PMID: 35347318) J Hepatol. 2021 Oct;75(4):848-855. (PMID: 33992699) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) World J Clin Cases. 2022 May 6;10(13):3969-3980. (PMID: 35665122) JGH Open. 2020 Oct 28;4(6):1047-1058. (PMID: 33319036) Biochem Biophys Res Commun. 2020 May 21;526(1):135-140. (PMID: 32199615) Am J Case Rep. 2021 Aug 01;22:e932531. (PMID: 34333508) J Hepatol. 2020 Sep;73(3):566-574. (PMID: 32298767) Liver Int. 2020 Aug;40(8):2038-2040. (PMID: 32352224) Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678. (PMID: 32405603) J Hepatol. 2021 May;74(5):1245-1246. (PMID: 33610679) J Clin Exp Hepatol. 2021 Nov-Dec;11(6):720-726. (PMID: 34177192) Cureus. 2022 May 10;14(5):e24873. (PMID: 35702473) J Hepatol. 2021 Feb;74(2):482-484. (PMID: 33223215) Rev Med Virol. 2017 Nov;27(6):. (PMID: 28905444) Signal Transduct Target Ther. 2020 Oct 31;5(1):255. (PMID: 33130825) Hepatology. 2021 Aug;74(2):1049-1064. (PMID: 33577086) Acta Biomed. 2020 Mar 19;91(1):157-160. (PMID: 32191675) Am J Gastroenterol. 2021 May 1;116(5):1077-1082. (PMID: 33464757) Gut. 2021 Apr;70(4):733-742. (PMID: 32641471) J Hepatol. 2020 Sep;73(3):702-705. (PMID: 32413378) Hepatol Int. 2020 Sep;14(5):690-700. (PMID: 32623632) Egypt Liver J. 2022;12(1):9. (PMID: 35096428) Indian J Gastroenterol. 2020 Jun;39(3):285-291. (PMID: 32803716) Hepatol Int. 2020 Sep;14(5):711-722. (PMID: 32623633) Sci China Life Sci. 2020 Nov;63(11):1678-1687. (PMID: 32567003) Eur J Gastroenterol Hepatol. 2021 Dec 1;33(12):1578-1581. (PMID: 32868652) J Hepatol. 2020 Sep;73(3):709-711. (PMID: 32445883) J Med Virol. 2021 Jun;93(6):3305-3311. (PMID: 33174624) Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566. (PMID: 32283325) Intern Med J. 2021 Jul;51(7):1182-1183. (PMID: 34278694) Front Med. 2022 Feb;16(1):111-125. (PMID: 34387851) Hepatology. 2021 Apr;73(4):1509-1520. (PMID: 32602604) Aliment Pharmacol Ther. 2020 Aug;52(4):584-599. (PMID: 32638436) JHEP Rep. 2020 Oct;2(5):100169. (PMID: 32835190) J Hepatol. 2020 Sep;73(3):705-708. (PMID: 32446714) SN Compr Clin Med. 2020;2(12):2726-2729. (PMID: 33173850) Exp Ther Med. 2022 Jun;23(6):385. (PMID: 35495599) Liver Int. 2020 Jun;40(6):1321-1326. (PMID: 32239591) World J Gastroenterol. 2021 Jun 14;27(22):3022-3036. (PMID: 34168405) Clin Gastroenterol Hepatol. 2020 Nov;18(12):2848-2851. (PMID: 32425707) J Viral Hepat. 2022 Jan;29(1):4-20. (PMID: 34352133) Hepatol Commun. 2020 Dec 10;5(2):177-188. (PMID: 33230491) Theranostics. 2021 Jan 1;11(1):316-329. (PMID: 33391477) Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) Front Med (Lausanne). 2021 Mar 12;8:626425. (PMID: 33777974) J Clin Transl Hepatol. 2021 Oct 28;9(5):760-768. (PMID: 34722191) Mod Pathol. 2020 Jun;33(6):1007-1014. (PMID: 32291399) J Transl Autoimmun. 2021;4:100116. (PMID: 34485887) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) Mediterr J Hematol Infect Dis. 2022 Jan 01;14(1):e2022003. (PMID: 35070210) Diseases. 2021 Jul 01;9(3):. (PMID: 34287285) Hepatol Int. 2020 Sep;14(5):621-637. (PMID: 32710250) J Hepatol. 2021 Jan;74(1):31-36. (PMID: 32777322) Am J Med Sci. 2022 Feb;363(2):94-103. (PMID: 34752738) |
| فهرسة مساهمة: | Keywords: COVID-19; Chronic liver disease; Cytokine storm; Drug-induced liver injury; Hypoxic hepatitis; Liver injury |
| تواريخ الأحداث: | Date Created: 20230123 Date Completed: 20230124 Latest Revision: 20230201 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9846934 |
| DOI: | 10.3748/wjg.v29.i2.257 |
| PMID: | 36687117 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2219-2840 |
|---|---|
| DOI: | 10.3748/wjg.v29.i2.257 |